Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

Inclusion Criteria

• Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for several months per year, for more than 1 year and are not attributed to allergy, infections or nasal abnormalities.
• TNSS score of >=4 following screening allergen challenge chamber.
• Positive skin prick test for seasonal pollen
• Positive RAST for seasonal pollen
• Healthy as determined by responsible physician with the exception of mild asthma and AR
• Male or female between 18 and 65 years of age inclusive.
• A female subject is eligible to participate if she is of:
• Non-childbearing potential defined as pre-menopausal females with a \documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol 14 drinks for males or >7 drinks for females.
• The subject has participated in a clinical trial and has received an investigational product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product prior to D1.
• Exposure to more than four new chemical entities within 12 months prior to D1.
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose of study medication.
• History of sensitivity to any of the study medications, or components
• Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
• Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
• Lactating females.
• Subject is mentally or legally incapacitated.
• Urine cotinine levels indicative of smoking